Wedbush reaffirmed their ourperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a report issued on Friday. They currently have a $253.00 price target on the biopharmaceutical company’s stock.

ICPT has been the topic of a number of other reports. Royal Bank Of Canada initiated coverage on Intercept Pharmaceuticals in a research report on Thursday. They set an outperform rating and a $244.00 price target on the stock. ValuEngine upgraded Intercept Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, June 2nd. BidaskClub upgraded Intercept Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 24th. Wells Fargo & Company restated an outperform rating on shares of Intercept Pharmaceuticals in a research report on Wednesday. Finally, Cantor Fitzgerald restated an underweight rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of Buy and a consensus price target of $207.75.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 8.55% on Friday, reaching $94.88. The company’s stock had a trading volume of 2,588,272 shares. The stock has a 50-day moving average of $108.47 and a 200 day moving average of $116.36. Intercept Pharmaceuticals has a 52 week low of $85.88 and a 52 week high of $172.95. The stock’s market capitalization is $2.38 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period in the prior year, the company earned ($3.14) EPS. On average, analysts expect that Intercept Pharmaceuticals will post ($14.06) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Receives Ourperform Rating from Wedbush” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/16/intercept-pharmaceuticals-inc-icpt-receives-ourperform-rating-from-wedbush.html.

In other news, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now directly owns 3,710 shares in the company, valued at approximately $470,279.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. Insiders sold a total of 48,013 shares of company stock worth $6,198,747 over the last 90 days. 9.20% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. FMR LLC raised its stake in Intercept Pharmaceuticals by 0.7% during the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after buying an additional 25,958 shares during the period. Carmignac Gestion raised its stake in Intercept Pharmaceuticals by 0.4% during the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after buying an additional 7,400 shares during the period. Vanguard Group Inc. raised its stake in Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares during the period. State Street Corp raised its stake in Intercept Pharmaceuticals by 7.3% during the 1st quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after buying an additional 54,523 shares during the period. Finally, First Trust Advisors LP raised its stake in Intercept Pharmaceuticals by 17.0% during the 2nd quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after buying an additional 41,856 shares during the period. Institutional investors and hedge funds own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.